Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-102: Bemarituzumab Plus Chemotherapy and Nivolumab vs Chemotherapy and Nivolumab in FGFR2b-Overexpressing Advanced Gastric/GEJ Cancer
2021-003477-61Phase 3Active
- Sponsor
- Amgen
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bemarituzumab in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by Amgen. Primary endpoint: Phase 1b primary endpoints. Started Feb 2022; status: active.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2021-003477-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003477-61.